PFE Stock Risk Analysis
PFE is a NYSE-listed stock with lower risk characteristics — a DredgeCap risk score of 3.8/10. No dominant structural financial risk is flagged in the most recent SEC filings; the primary considerations for existing shareholders are discussed in the analysis below, with supporting financial detail drawn from the 10-K and 10-Q.
Company Overview
Pfizer Inc. is a global biopharmaceutical company incorporated in Delaware and headquartered in New York, New York, with common stock listed on the New York Stock Exchange under the ticker PFE. The company develops, manufactures, and commercializes medicines and vaccines across a broad range of therapeutic areas through its Biopharma reportable segment, which generated $44,056 million in revenues for the nine months ended September 28, 2025. Pfizer also earns alliance revenues from co-promotion agreements and royalty revenues, with total revenues of $45,022 million for the nine-month period ended September 28, 2025 [Source: 10-Q, filed 2025-11-04, Condensed Consolidated Statements of Operations and Segment disclosures].
AI-generated summary based on SEC filings. May contain errors. See disclosure
Investment Risk Score
NEUTRALFull PFE Stock Risk Report
The integrated analysis — primary risk driver in plain language, expected shareholder outcome, what would materially change the view, and what moves the stock. One-time $7.99, lifetime access for PFE.
PFE Risk Summary
Pfizer is a large-scale established pharmaceutical company with $208 billion in total assets, $86.5 billion in shareholders' equity, and a capital structure consisting of conventional fixed-rate debt with no shareholder-adverse instruments — characteristics consistent with a financially stable, dividend-capable large-cap. The primary risk for existing shareholders is not structural or financial…